Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...

William Blair analyst Andy Hsieh maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today. The ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Cardiff Oncology (CRDF – Research Report) today. The company’s shares closed today ...